Although there are currently no Lp(a)-lowering therapies available, measuring Lp(a) levels can still benefit patients by identifying those who would benefit from improved risk factor control. Kausik K. Ray emphasized the importance of measuring Lp(a) at least once in a lifetime, especially for individuals with a family history of cardiovascular disease. Traditional risk factors alongside untreated elevated Lp(a) can significantly increase ASCVD risk. LDL lowering, monoclonal antibodies like inclisiran, and therapies targeting Lp(a) production are being studied to address this issue. Lowering Lp(a) levels with therapies like alirocumab has shown promising results in reducing cardiovascular events.
Source link
‘De-risk’ patients with high Lp(a) to prevent atherosclerotic events
